TABLE 2.
Clinical efficacy endpoints by treatment group
| Measure | Value for groupb
|
Δ (95% CI)c | |
|---|---|---|---|
| Artesunate suppositories | i.m. artemether | ||
| PCT50 (h) | 9.1 ± 4.9 | 13.5 ± 7.9 | −4.3 (−7.5 to −1.2)* |
| PCT90 (h) | 15.6 ± 7.4 | 20.4 ± 8.0 | −4.8 (−8.5 to −1.1)** |
| PC%12 | 17 (0-190)* | 56 (0-3,020) | |
| PC%24 | 0.5 (0-40) | 1.2 (0-580) | |
| Time to per os status (days) | 1.35 ± 0.76 | 1.69 ± 0.82 | −0.25 (−0.62 to +0.11) |
| PCT (h) | 30.3 ± 14.2 | 32.8 ± 12.9 | −2.5 (−8.8 to +3.8) |
| FCT (h)a | 18.3 ± 10.7 | 15.6 ± 9.2 | +2.8 (−1.9 to +7.5) |
a
FCT, fever clearance time.
b
Data are expressed as means ± standard deviations or medians (ranges).
c
Differences between groups (Δ) and their 95% confidence intervals (CI) are shown. *, P < 0.01; **, P < 0.02.